Ferroptosis Regulator Information
General Information of the Ferroptosis Regulator (ID: REG10480)
Full List of the Ferroptosis Target of This Regulator and Corresponding Disease/Drug Response(s)
PRDX5
can regulate the following target(s), and cause disease/drug response(s). You can browse detail information of target(s) or disease/drug response(s).
Browse Target
Browse Disease
Browse Drug
Unspecific Target [Unspecific Target]
In total 1 item(s) under this target | ||||
Experiment 1 Reporting the Ferroptosis Target of This Regulator | [1] | |||
Responsed Disease | Hepatocellular carcinoma | ICD-11: 2C12 | ||
Responsed Drug | Erastin | Investigative | ||
Pathway Response | Fatty acid metabolism | hsa01212 | ||
Apoptosis | hsa04210 | |||
Cell Process | Cell ferroptosis | |||
Cell apoptosis | ||||
In Vitro Model |
Hep-G2 cells | Hepatoblastoma | Homo sapiens | CVCL_0027 |
Huh-7 cells | Hepatocellular carcinoma | Homo sapiens | CVCL_0336 | |
Hep 3B2.1-7 cells | Hepatocellular carcinoma | Homo sapiens | CVCL_0326 | |
Response regulation | Erastin upregulated the lncRNA GABPB1-AS1, which downregulated GABPB1 protein levels by blocking GABPB1 translation, leading to the downregulation of the gene encoding Peroxiredoxin-5 (PRDX5) peroxidase and the eventual suppression of the cellular antioxidant capacity. GABPB1 and GABPB1-AS1 are attractive therapeutic targets for hepatocellular carcinoma. | |||
Hepatocellular carcinoma [ICD-11: 2C12]
In total 1 item(s) under this disease | ||||
Experiment 1 Reporting the Ferroptosis-centered Disease Response | [1] | |||
Target Regulator | Peroxiredoxin-5, mitochondrial (PRDX5) | Protein coding | ||
Responsed Drug | Erastin | Investigative | ||
Pathway Response | Fatty acid metabolism | hsa01212 | ||
Apoptosis | hsa04210 | |||
Cell Process | Cell ferroptosis | |||
Cell apoptosis | ||||
In Vitro Model |
Hep-G2 cells | Hepatoblastoma | Homo sapiens | CVCL_0027 |
Huh-7 cells | Hepatocellular carcinoma | Homo sapiens | CVCL_0336 | |
Hep 3B2.1-7 cells | Hepatocellular carcinoma | Homo sapiens | CVCL_0326 | |
Response regulation | Erastin upregulated the lncRNA GABPB1-AS1, which downregulated GABPB1 protein levels by blocking GABPB1 translation, leading to the downregulation of the gene encoding Peroxiredoxin-5 (PRDX5) peroxidase and the eventual suppression of the cellular antioxidant capacity. GABPB1 and GABPB1-AS1 are attractive therapeutic targets for hepatocellular carcinoma. | |||
Erastin
[Investigative]
In total 1 item(s) under this drug | ||||
Experiment 1 Reporting the Ferroptosis-centered Drug Response | [1] | |||
Drug for Ferroptosis | Inducer | |||
Response Target | Unspecific Target | |||
Responsed Disease | Hepatocellular carcinoma | ICD-11: 2C12 | ||
Pathway Response | Fatty acid metabolism | hsa01212 | ||
Apoptosis | hsa04210 | |||
Cell Process | Cell ferroptosis | |||
Cell apoptosis | ||||
In Vitro Model |
Hep-G2 cells | Hepatoblastoma | Homo sapiens | CVCL_0027 |
Huh-7 cells | Hepatocellular carcinoma | Homo sapiens | CVCL_0336 | |
Hep 3B2.1-7 cells | Hepatocellular carcinoma | Homo sapiens | CVCL_0326 | |
Response regulation | Erastin upregulated the lncRNA GABPB1-AS1, which downregulated GABPB1 protein levels by blocking GABPB1 translation, leading to the downregulation of the gene encoding Peroxiredoxin-5 (PRDX5) peroxidase and the eventual suppression of the cellular antioxidant capacity. GABPB1 and GABPB1-AS1 are attractive therapeutic targets for hepatocellular carcinoma. | |||